From this perspective, future experimental models should directly assess the relationship between IL‐4/IL‐13 suppression and VCAM‐1 levels in serum and tissue among patients with T2 severe asthma, eosinophilic COPD, and EoE, to clarify the hypothesized role of this mechanism in the pathogenesis of blood eosinophilia following dupilumab administration. The gene discussed is IL13; the disease is eosinophilic esophagitis.